Related Experiment Videos
Deferoxamine-induced bone changes in haemodialysis patients: a histomorphometric study
S A Charhon1, P Chavassieux, G Boivin
1INSERM Unité 234, Faculté A. Carrel, Lyon, France.
Clinical Science (London, England : 1979)
|August 1, 1987
Summary
Deferoxamine therapy effectively reduced bone aluminium deposits and improved mineralization in patients with chronic kidney disease and osteomalacia. Hyperparathyroidism correlated with a greater positive response to this treatment.
Area of Science:
- Nephrology
- Histopathology
- Bone Metabolism
Background:
- Chronic kidney disease (CKD) patients undergoing hemodialysis often develop aluminum bone disease.
- Aluminum deposition in bone impairs mineralization and bone turnover.
Purpose of the Study:
- To evaluate the histological effects of deferoxamine (DFO) therapy on bone biopsies in CKD patients with aluminum bone disease.
- To assess the impact of DFO on bone mineralization, osteoid parameters, and bone formation rates.
Main Methods:
- Transiliac bone biopsies were obtained from 16 CKD patients with aluminum deposits after double tetracycline labeling.
- Patients received intravenous deferoxamine therapy (1-6g weekly) for a mean of 7.6 months.
- Histological analysis assessed aluminum deposits, osteoid volume, osteoid surfaces, and bone formation rates.
Main Results:
- Deferoxamine therapy significantly reduced bone aluminum deposits, osteoid volume, and osteoid surface thickness.
- Significant increases in osteoblastic surfaces and bone formation rates were observed.
- In patients with osteomalacia, deferoxamine increased resorption parameters and parathyroid hormone levels.
Conclusions:
- Deferoxamine therapy is effective in reducing bone aluminum burden and improving mineralization in low-turnover osteomalacia associated with CKD.
- The degree of hyperparathyroidism influences the response to deferoxamine therapy, with higher levels correlating with greater aluminum reduction and improved mineralization.